References
- Ehrmann D A. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223–1236
- Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853–861
- Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141–146
- Baillargeon J P, Nestler J E. Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?. J Clin Endocrinol Metab 2006; 91: 22–24
- Larner J. Multiple pathways in insulin signaling – fitting the covalent and allosteric puzzle pieces together. Endocr J 1994; 2: 167–171
- Baillargeon J P, Diamanti-Kandarakis E, Ostlund R E, Jr, Apridonidze T, Iuorno M J, Nestler J E. Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006; 29: 300–305
- Iuorno M J, Jakubowicz D J, Baillargeon J P, Dillon P, Gunn R D, Allan G, Nestler J E. Effect of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8: 417–423
- Yoshida K, Yamaguchi M, Morinaga T, Ikeuchi M, Kinehara M, Ashida H. Genetic modification of Bacillus subtilis for production of d-chiro-inositol, an investigation drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. Appl Environ Microbiol 2006; 72: 1310–1315
- Chiu T T, Rogers M S, Law E L, Briton-Jones C M, Cheung L P, Haines C J. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Human Reprod 2002; 17: 1591–1596
- Chiu T T, Rogers M S, Briton-Jones C, Haines C. Effect of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Human Reprod 2003; 18: 408–416
- Tummon I, Gavrilova-Jordan L, Allemand M C, Session D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005; 84: 611–616
- Battaglia C, Mancini F, Persico N, Zaccaria V, de Aloysio D. Ultrasound evaluation of PCO, PCOS and OHSS. Reprod Biomed Online 2004; 9: 614–619
- Cheang K I, Nestler J E. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?. Reprod Biomed Online 2004; 8: 440–447
- Baillargeon J P. Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs 2005; 6: 1012–1022
- Legro R S, Barnhart H X, Schlaff W D, Carr B R, Diamond M P, Carson S A, Steinkampf M P, Coutifaris C, McGovern P G, Cataldo N A, , Cooperative Multicenter Reproductive Medicine Network, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356: 551–566
- Pesant M H, Baillargeon J P. Ovulation induction in polycystic ovary syndrome – how do metformin and clomifene citrate compare?. Nat Clin Pract Endocr Metab 2007; 3: 512–513
- Lord J M, Flight I H, Norman R J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. B Med J 2003; 327: 951–957
- Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340: 1314–1320
- Gerli S, Mignosa M, Di Renzo G C. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003; 7: 151–159